Global Phase 2/3 Clinical Trial for COVID-19 Vaccine Starts at NYU Langone Health
July 28, 2020
July 28, 2020
NEW YORK, July 28 -- NYU Langone Health, an academic medical center affiliated with New York University, issued the following news release on July 27:
The first U.S. patients have been dosed in a phase 2/3 clinical trial testing whether a lead messenger RNA (mRNA) vaccine candidate can prevent infection with the virus that causes 2019 coronavirus disease (COVID-19).
NYU Grossman School of Medicine, under the auspices of NYU Langone Health's Vaccine Center, served as one . . .
The first U.S. patients have been dosed in a phase 2/3 clinical trial testing whether a lead messenger RNA (mRNA) vaccine candidate can prevent infection with the virus that causes 2019 coronavirus disease (COVID-19).
NYU Grossman School of Medicine, under the auspices of NYU Langone Health's Vaccine Center, served as one . . .